搜索
应用近红外荧光相关光谱监测人血液中纳米药物载体
- 分类:FCS技术应用于纳米颗粒分析
- 发布时间:2023-05-06 10:26
- 访问量:
德国马克斯·普朗克聚合物研究所的Hans-Jürgen Butt 、Kaloian Koynov团队报道了使用近红外荧光相关光谱(NIR-FCS)定量分析人类血液中纳米药物载体(NCs)的研究。NCs在多种疾病的治疗中有独特作用,它在人类血液中可能发生聚集、相互作用等变化,因此有必要在血液中直接检测NCs。FCS技术可以监测溶液中分子的相互作用、粒径变化等,但血液会对可见光有强烈的吸收、散射,因此少见传统FCS在血液实验中的报道。本文详细介绍了NIR-FCS实验的方法,包括测定近红外荧光分子扩散系数、共聚焦体积等。另外,本文通过在流动血液中采集FCS数据,并使用特定的数学模型,回避了血液中血细胞的影响,使得无需分离血细胞和血浆便可进行FCS实验。该团队通过上述的方法,进一步探索了NIR-FCS定量分析小分子于血液发生相互作用、药物载体稳定性的可能性。
Abstract
Nanocarrier-based drug delivery is a promising therapeutic approach that offers unique possibilities for the treatment of various diseases. However, inside the blood stream, nanocarriers’ properties may change significantly due to interactions with proteins, aggregation, decomposition or premature loss of cargo. Thus, a method for precise, in situ characterization of drug nanocarriers in blood is needed. Here we show how the fluorescence correlation spectroscopy that is a well-established method for measuring the size, loading efficiency and stability of drug nanocarriers in aqueous solutions can be used to directly characterize drug nanocarriers in flowing blood. As the blood is not transparent for visible light and densely crowded with cells, we label the nanocarriers or their cargo with near-infrared fluorescent dyes and fit the experimental autocorrelation functions with an analytical model accounting for the presence of blood cells. The developed methodology contributes towards quantitative understanding of the in vivo behavior of nanocarrier-based therapeutics.
了解更多详情请微信关注单分子荧光公众号或点击下方链接。
https://mp.weixin.qq.com/s?__biz=MzkzNzI0NTc5Mg==&mid=2247485768&idx=1&sn=448ad99f4ec075a9b2b9e09b98a1ebc6&chksm=c2932447f5e4ad51b592d09e0b3775e2c90421179f0e471331e366eb82bb7e8d9b4aa6de32d7&token=928242522&lang=zh_CN#rd
contact us
联系我们
中科奥辉以创新引领行业,以科技服务社会
公司名称:广东中科奥辉科技有限公司
在线留言
版权所有 © 广东中科奥辉科技有限公司 粤ICP备17145470号 网站建设:中企动力 中山